- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07646301
Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer (QUARTZ-CC)
Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Prospective Single-Arm Phase II Trial
Purpose:
To evaluate the efficacy and safety of neoadjuvant treatment with iparomlimab and tuvonralimab (QL1706), a dual PD1and CTLA4 bispecific antibody, in combination with paclitaxel and either cisplatin or carboplatin (TP/TC regimen) for patients with locally advanced cervical cancer.
Eligibility Criteria:
Women aged 18 to 70 years with newly diagnosed, histologically confirmed cervical cancer (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma), FIGO stage IB3 or IIA2, with no evidence of significant lymph node involvement (pelvic and paraaortic lymph nodes <1.5 cm in short diameter), and who have not received any prior anticancer therapy.
Study Procedures:
Participants will receive up to 4 cycles of QL1706 plus TP/TC chemotherapy (once every 3 weeks) prior to surgery. After 2 cycles, clinical assessment will be performed to evaluate tumor response. If tumor shrinkage is observed, treatment may continue for 2 additional cycles, followed by imaging evaluation. Depending on the response, participants with complete or partial response may undergo less extensive surgery (cervical conization plus sentinel lymph node biopsy) rather than standard radical hysterectomy. After surgery, participants who achieve a major pathological response will receive QL1706 maintenance therapy as a single agent for up to 8 additional cycles (once every 3 weeks). For participants with insufficient tumor response, standard radical hysterectomy will be performed. Postoperative adjuvant therapy (radiation or chemotherapy) will follow standard clinical guidelines.
Primary and Secondary Objectives:
The primary endpoint is the pathological complete response (pCR) rate in the resected tissue following neoadjuvant treatment. Secondary endpoints include safety (treatment related adverse events), objective response rate (ORR), 3 years overall survival, 3 years disease free survival, and quality of life.
Study Duration:
Total participation time depends on treatment response and surgical scheduling, with an expected duration of approximately 9 to 12 months (including neoadjuvant treatment, surgery, and potential maintenance therapy).
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Detailed Description Background Cervical cancer remains the fourth most common malignancy among women worldwide. In 2022, approximately 660,000 new cases and 350,000 deaths were reported globally, with the heaviest burden observed in developing regions, particularly Asia, which accounts for nearly 60% of global cases and deaths. China alone contributes 22.8% of global incidence and 16% of global mortality.
Locally advanced cervical cancer (LACC, FIGO stages IB3 and IIA2) constitutes approximately 50% of all cervical cancer cases in China. Current standard of care is concurrent chemoradiotherapy (CCRT); however, 23.3%-34.4% of patients still experience disease recurrence or metastasis. Neoadjuvant chemotherapy (NACT) followed by radical surgery has been investigated as an alternative strategy, yet 9.8%-30.6% of patients fail to respond to NACT, potentially delaying effective local treatment. Moreover, over 30% of patients who undergo surgery require adjuvant radiotherapy, raising concerns regarding treatment burden and health economics.In recent years, immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. Anti-PD-1/PD-L1 and anti-CTLA-4 antibodies exert complementary mechanisms of action. Emerging evidence supports the combination of neoadjuvant chemotherapy and immunotherapy for LACC. In the PACS study (presented at ASCO 2024), the pathological complete response (pCR) rate was 36.2%, and the optimal pathological response rate (residual tumor <3 mm) was 53.2%. Other studies, including NACI, MITO CERV3, and NATCI, have reported similarly encouraging pCR rates. Given the unmet medical need for more effective and less toxic neoadjuvant regimens, further evaluation of novel immunotherapy combinations such as the dual PD-1/CTLA-4 bispecific antibody iparomlimab and tuvonralimab (QL1706) in combination with platinum-based chemotherapy is warranted.
Detailed Treatment and Response-Adapted Algorithm Following neoadjuvant treatment (up to 4 cycles of paclitaxel plus cisplatin or carboplatin combined with QL1706), patients undergo clinical assessment after 2 cycles. If tumor shrinkage is observed, patients continue for 2 additional cycles followed by imaging evaluation. Based on imaging response: complete response leads to cervical conization plus sentinel lymph node biopsy or pelvic lymph node dissection; partial response leads to radical hysterectomy or trachelectomy plus sentinel lymph node biopsy or pelvic lymph node dissection. Patients achieving optimal pathological response (defined as pathological complete response or residual tumor depth ≤3 mm) receive 2 additional cycles of the same regimen followed by QL1706 maintenance therapy for 8 cycles. Non-optimal responders receive adjuvant therapy per NCCN guidelines. Patients who cannot tolerate surgery or have contraindications receive radical radiotherapy.
Sample Size Justification and Statistical Framework The sample size was calculated using Simon's two-stage optimal design (one-sided alpha=0.05, power=80%; null hypothesis pCR=30% vs. alternative pCR=43%). The first stage enrolls 33 patients; if 10 or more pCR events are observed, enrollment continues to a total of 94 evaluable patients. Accounting for 10% dropout, total target enrollment is 103 patients.
Data and Safety Monitoring An independent Data Monitoring Committee will oversee patient safety and conduct periodic reviews. The Committee may recommend early termination for efficacy, futility, or safety concerns. The study will be conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines, with written informed consent obtained from all participants.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Jihong Liu, Ph.D.
- Telefonnummer: +86 20 87341779
- E-post: liujih@sysucc.org.cn
Studera Kontakt Backup
- Namn: Yun Zhou, M.D.
- Telefonnummer: +8618520122069 +86 20 87343105
- E-post: zhouyun@sysucc.or.cn
Studieorter
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510060
- Rekrytering
- Sun Yat-sen University Cancer Center
-
Kontakt:
- Chun-Yan Chen
- Telefonnummer: +86 20 87341779
- E-post: chenchuny@sysucc.org.cn
-
Huvudutredare:
- Jihong Liu, Ph.D.
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Age 18 to 70 years.
- Histologically or cytologically confirmed cervical cancer, FIGO stage IB3 or IIA2.
- Imaging findings showing pelvic lymph node short-axis diameter < 1.5 cm and para-aortic lymph node short-axis diameter < 1.5 cm.
- Pathological diagnosis of cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.
- No prior anti-tumor therapy.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
Exclusion Criteria:
- Presence of other concurrent malignancies.
- Pregnant or peripartum women.
- History of myocardial infarction or stroke, unstable angina, decompensated heart failure, or deep vein thrombosis.
- Presence of NCI-CTCAE version 5.0 grade ≥2 arrhythmia, any grade of atrial fibrillation, or clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.
- Active unresolved hepatitis, defined as progressive decrease in appetite, general weakness, nausea, acid reflux, aversion to oily foods, abdominal distension, or abnormal liver function with jaundice (e.g., scleral or urinary jaundice); for hepatitis B, HBV DNA > 1000 IU/mL.
- Hepatic insufficiency (aspartate aminotransferase/alanine aminotransferase > 2.5 × upper limit of normal).
- Renal insufficiency (serum creatinine > 2 × upper limit of normal).
- History of chronic pulmonary disease with restrictive respiratory dysfunction.
- History of major organ transplantation or autoimmune disease.
- History of severe mental illness or cerebral dysfunction.
- History of substance abuse or drug addiction.
- Use of immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes (dose > 10 mg prednisone or equivalent) within 2 weeks prior to enrollment, with ongoing use.
- Coagulation abnormality (INR > 2.0, PT > 16 seconds), bleeding tendency, or ongoing thrombolytic or anticoagulant therapy (prophylactic low-dose aspirin and low-molecular-weight heparin are permitted).
- Congenital or acquired immunodeficiency (e.g., HIV infection).
- Receipt of inactivated vaccine within 30 days prior to the first dose of study treatment.
- Inability or unwillingness to provide written informed consent or comply with study requirements.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: QL1706 + TP/TC Neoadjuvant Chemoimmunotherapy
Participants receive up to 4 cycles of neoadjuvant therapy (once every 3 weeks) with iparomlimab and tuvonralimab (QL1706 250 mg, IV) plus paclitaxel (150-175 mg/m², IV) and either cisplatin (70-75 mg/m², IV, split over 2 days) or carboplatin (AUC=5, IV).
Treatment response is assessed after 2 cycles.
For patients achieving tumor shrinkage, neoadjuvant therapy continues for 2 additional cycles followed by imaging.
Patients achieving complete response (CR) undergo cervical conization plus sentinel lymph node biopsy (SLNB) or pelvic lymph node dissection (PLND).
Those achieving partial response (PR) or non-optimal pathological response after surgery undergo radical hysterectomy/trachelectomy plus SLNB/PLND.
Participants who achieve optimal pathological response (pCR or residual tumor depth ≤3 mm) after surgery receive QL1706 maintenance therapy for up to 8 cycles (once every 3 weeks).
Patients who cannot tolerate surgery or have contraindications undergo radical radiotherapy.
|
250 mg administered intravenously over at least 30 minutes on Day 1 of each 21-day cycle for up to 4 cycles as neoadjuvant therapy, and up to 8 cycles as maintenance therapy (for patients achieving optimal pathological response).
150-175 mg/m² administered intravenously over at least 3 hours on Day 1 of each 21-day cycle for up to 4 cycles, with standard premedication to prevent hypersensitivity.
70-75 mg/m² administered intravenously over at least 1 hour, split over two consecutive days (Day 1 and Day 2) of each 21-day cycle for up to 4 cycles. Cisplatin or Carboplatin according to investigator's choice AUC=5 administered intravenously over at least 1 hour on Day 1 of each 21-day cycle for up to 4 cycles. Cisplatin or Carboplatin according to investigator's choice |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Pathological Complete Response (pCR) Rate
Tidsram: At the time of surgery, following completion of neoadjuvant treatment (each cycle is 21 days; patients receive 2 to 4 cycles)
|
Proportion of patients with no residual invasive tumor cells in the surgically resected primary tumor specimen following neoadjuvant therapy.
|
At the time of surgery, following completion of neoadjuvant treatment (each cycle is 21 days; patients receive 2 to 4 cycles)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Major Pathological Response (MPR) Rate
Tidsram: At the time of surgery, following completion of neoadjuvant treatment (each cycle is 21 days)
|
Proportion of patients with residual tumor depth ≤3 mm in the surgically resected primary tumor specimen following neoadjuvant therapy.
|
At the time of surgery, following completion of neoadjuvant treatment (each cycle is 21 days)
|
|
Objective Response Rate (ORR)
Tidsram: After 4 cycles of neoadjuvant treatment (each cycle is 21 days)
|
Proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST 1.1 criteria on imaging after neoadjuvant therapy.
|
After 4 cycles of neoadjuvant treatment (each cycle is 21 days)
|
|
3-Year Overall Survival (OS) Rate
Tidsram: From date of first dose to date of death from any cause, assessed up to 36 months
|
Overall survival rate at 3 years from study enrollment.
|
From date of first dose to date of death from any cause, assessed up to 36 months
|
|
3-Year Disease-Free Survival (DFS) Rate
Tidsram: From date of surgery to date of recurrence or death, assessed up to 36 months
|
Disease-free survival rate at 3 years from study enrollment.
|
From date of surgery to date of recurrence or death, assessed up to 36 months
|
|
Treatment-Related Adverse Events (TRAEs)
Tidsram: From first dose of study treatment until 90 days after last dose (each cycle is 21 days; up to 6 neoadjuvant cycles + up to 8 maintenance cycles; total up to approximately 12 months).
|
Incidence, grade, and relationship of adverse events (both conventional and immune-related TRAEs) assessed by NCI-CTCAE v5.0.
|
From first dose of study treatment until 90 days after last dose (each cycle is 21 days; up to 6 neoadjuvant cycles + up to 8 maintenance cycles; total up to approximately 12 months).
|
|
Patient-Reported Outcomes (PROs)-Change in Quality of Life as Measured by the EORTC QLQ-C30
Tidsram: Baseline (pre-treatment), and at 3, 6, 12, 24, and 36 months post-treatment. For assessments occurring during the treatment phase (each cycle is 21 days; up to 6 neoadjuvant cycles followed by up to 8 maintenance cycles).
|
Change from baseline in global health status/quality of life and functional/symptom scores measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).
All scales range from 0 to 100.
For the global health status and functional subscales, higher scores mean a better outcome.
For the symptom subscales, higher scores mean a worse outcome.
|
Baseline (pre-treatment), and at 3, 6, 12, 24, and 36 months post-treatment. For assessments occurring during the treatment phase (each cycle is 21 days; up to 6 neoadjuvant cycles followed by up to 8 maintenance cycles).
|
|
Patient-Reported Outcomes (PROs)-Change in Cervical Cancer-Specific Symptoms as Measured by the EORTC QLQ-CX24
Tidsram: Baseline (pre-treatment), and at 3, 6, 12, 24, and 36 months post-treatment. For assessments occurring during the treatment phase (each cycle is 21 days; up to 6 neoadjuvant cycles followed by up to 8 maintenance cycles).
|
Change from baseline in symptom and functional scores measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Cervical Cancer Module 24 (EORTC QLQ-CX24).
All scales range from 0 to 100.
For functional scales (including sexual activity), higher scores mean a better outcome.
For symptom scales (including pain, lymphoedema, peripheral neuropathy, menopausal symptoms, and sexual worry), higher scores mean a worse outcome.
|
Baseline (pre-treatment), and at 3, 6, 12, 24, and 36 months post-treatment. For assessments occurring during the treatment phase (each cycle is 21 days; up to 6 neoadjuvant cycles followed by up to 8 maintenance cycles).
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Predictive Biomarkers of Response
Tidsram: Baseline and at time of surgery
|
Association of treatment response with baseline and post-treatment biomarkers including PD-L1 expression, tumor mutation burden (TMB), tertiary lymphoid structures (TLS), and imaging features (radiomics).
|
Baseline and at time of surgery
|
|
Changes in Ovarian Function in Younger Patients
Tidsram: Baseline and within 1 month after surgery
|
Comparison of ovarian function (e.g., anti-Müllerian hormone, follicle-stimulating hormone, estradiol levels) before and after neoadjuvant treatment in premenopausal patients.
|
Baseline and within 1 month after surgery
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Allmänna publikationer
- Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10. doi: 10.1016/0197-2456(89)90015-9.
- Lou H, Zhou Y, Li D, et al. 251 Efficacy and safety of iparomlimab and tuvonralimab in previously treated patients with recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase 2 clinical trial (DUBHE-C- 206). Int J Gynecol Cancer. 2024;34(Suppl 1):A5.1.
- Pan YC, Dai Z, Ma H, Zheng J, Leng J, Xie C, Yuan Y, Yang W, Yalikun Y, Song X, Han CB, Shang C, Yang Y. Self-powered and speed-adjustable sensor for abyssal ocean current measurements based on triboelectric nanogenerators. Nat Commun. 2024 Jul 20;15(1):6133. doi: 10.1038/s41467-024-50581-w.
- Cui B, Xian C, Han B, Shu C, Qian Y, Ouyang Z, Wang X. High-resolution emission inventory of biogenic volatile organic compounds for rapidly urbanizing areas: A case of Shenzhen megacity, China. J Environ Manage. 2024 Feb;351:119754. doi: 10.1016/j.jenvman.2023.119754. Epub 2023 Dec 10.
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Livmodersjukdomar
- Genitala sjukdomar, kvinnor
- Genitala neoplasmer, hona
- Livmoderhalssjukdomar
- Uterina neoplasmer
- Uterina cervikala neoplasmer
- Organiska kemikalier
- Kolväten
- Cykloparaffiner
- Kolväten, alicyklisk
- Kolväten, cykliska
- Terpener
- Oorganiska kemikalier
- Klorföreningar
- Kväveföreningar
- Koordinationskomplex
- Taxoids
- Cyklodekaner
- Gentare
- Platinaföreningar
- Karboplatin
- Paklitaxel
- Cisplatin
Andra studie-ID-nummer
- B2026-154-01
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .